(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals - 2Top Breakfast Food: What's Your Morning Enjoyment?
- 3Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- 4NASA shares first photos of Earth taken by Artemis II
- 5Trump signs a law returning whole milk to school lunches
- Astronauts head home early after medical issue
- Watch interstellar comet 3I/ATLAS speed away from the sun in free telescope livestream on Nov. 16
- Instructions to Decide the Best SUV Size for Seniors
- 10 times the sky amazed us in 2025
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- Good ways to respond if your kid brings home less-than-ideal grades
- Former Israeli judge does not expect Netanyahu to be pardoned
- 3D Printers for Specialists
